🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Karthik V. Giridhar

ORCID: 0000-0003-4640-9197

Also affiliated with WinnMed, Mayo Clinic in Arizona, Mayo Clinic in Florida

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 13 papers. Top paper: “Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial”.

Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

Nature Medicine(2024)10.1038/s41591-024-03267-1

N/A

1.4DataRank · unranked

43 citations

Meghna S. Trivedi, Christina Yau, Rita Nanda, Hope S. Rugo, Marie Davidian +55 more

Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer

JAMA Oncology(2023)10.1001/jamaoncol.2022.7949

N/A

1.4DataRank · unranked

52 citations

Vera J. Suman, Antonino B. D’Assoro, Jodi M. Carter, Karthik V. Giridhar, Brendan P. McMenomy +18 more

Alternating 17β-Estradiol and Aromatase Inhibitor Therapies Is Efficacious in Postmenopausal Women with Advanced Endocrine-Resistant ER+ Breast Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0112

N/A

0.523DataRank · unranked

8 citations

Peter A. Kaufman, Karthik V. Giridhar, Jonathan D. Marotti, Mary D. Chamberlin, Bradley A. Arrick +7 more

Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer

npj Breast Cancer(2021)10.1038/s41523-021-00337-2

N/A

0.510DataRank · unranked

29 citations

Claudine Isaacs, Denise M. Wolf, Christina Yau, Paul Haluska, Karthik V. Giridhar +50 more

Blockade of tumor cell-intrinsic PD-L1 signaling enhances AURKA-targeted therapy in triple negative breast cancer

Frontiers in Oncology(2024)10.3389/fonc.2024.1384277

N/A

0.269DataRank · unranked

5 citations

Minzhi Zhang, Mohammad Jalalirad, Roberto Leon Ferre, Royal Shrestha, Tufia C. Haddad +12 more

Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602)

The Oncologist(2023)10.1093/oncolo/oyad140

N/A

0.229DataRank · unranked

3 citations

Jennifer Le‐Rademacher, Fabrice Smieliauskas, Kathryn J. Ruddy, Thomas J. Saphner, Heshan Liu +10 more

Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC)

npj Breast Cancer(2025)10.1038/s41523-025-00748-5

N/A

0DataRank · unranked

39 citations

Reshma Mahtani, Samantha Fisch, Naomi Dempsey, Sarah Premji, Angelina Raimonde +17 more

Plasma assay of methylated DNA markers detects recurrent metastatic breast cancer

npj Breast Cancer(2025)10.1038/s41523-025-00866-0

N/A

0DataRank · unranked

0 citations

Jason P. Sinnwell, Seth W. Slettedahl, William R. Taylor, Douglas W. Mahoney, Patrick H. Foote +14 more

Olanzapine with or without an NK-1 receptor antagonist for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy: A phase III randomized, double-blind, placebo-controlled trial (ALLIANCE A221602).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.12107

N/A

0DataRank · unranked

1 citations

Jennifer Le‐Rademacher, Fabrice Smieliauskas, Kathryn J. Ruddy, Thomas J. Saphner, Heshan Liu +9 more

Clinical Management of Metastatic Hormone Receptor-Positive, HER2-negative Breast Cancer (MBC) After CDK 4/6 inhibitors: A Retrospective Single-Institution Study

Research Square(2022)10.21203/rs.3.rs-1601792/v1

N/A

0DataRank · unranked

0 citations

S. Liddell, Roberto A. Leon‐Ferre, Ciara C. O’Sullivan, Kathryn J. Ruddy, Tufia C. Haddad +6 more

Dynamic assessment of serum chromogranin A and treatment response with abiraterone acetate in metastatic castration‐resistant prostate cancer

The Prostate(2023)10.1002/pros.24498

N/A

0DataRank · unranked

1 citations

Brian A. Costello, Fernando Quevedo, Lance C. Pagliaro, Cristobal T. Sanhueza, Richard M. Weinshilboum +6 more

353P Clinical outcomes of treatment with CDK4/6 inhibitors in metastatic breast cancer among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2

Annals of Oncology(2024)10.1016/j.annonc.2024.08.301

N/A

0DataRank · unranked

3 citations

Gerald Choong, R. Koch, Shabnam Yadav, Arya Karki, Ranga Raju Rao +11 more

Anastrozole Dose Escalation for Optimal Estrogen Suppression in Postmenopausal Early-Stage Breast Cancer: A Prospective Trial

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0341

N/A

0DataRank · unranked

4 citations

Vera J. Suman, Karthik V. Giridhar, Kostandinos Sideras, Donald W. Northfelt, Brenda Ernst +15 more